Complete the Renazorb clinical bioequivalence study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 31 Mar 2022
- Due
- 31 Dec 2022
- Delivered
- 28 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“with a goal to complete the study by the end of 2022”
What we found
Evidence strength A What the grades mean
Unicycive completed the Renazorb bioequivalence study and announced primary endpoint achievement on December 28, 2022, within the stated deadline.
-
A Unicycive Therapeutics Q3 2022 Business Update (SEC Filing)
“Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB (lanthanum dioxycarbonate)” ✓ confirmed on the page
-
B Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
“Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the primary endpoint was met in the Company's pivotal bioequivalence (BE) study comparing Renazorb to Fosrenol” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Renazorb clinical bioequivalence study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-UNCY-002766 · Corrections policy